
bioMérieux S.A (BIM) | Financial Analysis & Statements
bioMérieux S.A. | Large-cap | Healthcare
bioMérieux S.A. | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
5.8B
Total Liabilities
1.6B
Shareholders Equity
4.2B
Debt to Equity
0.37
Cash Flow Metrics
Revenue & Profitability Trend
bioMérieux S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 4.0B | 3.7B | 3.6B | 3.4B | 3.1B |
Cost of Goods Sold | 1.8B | 1.6B | 1.6B | 1.4B | 1.4B |
Gross Profit | 2.2B | 2.1B | 2.0B | 2.0B | 1.8B |
Gross Margin % | 55.7% | 56.0% | 56.0% | 59.3% | 56.2% |
Operating Expenses | |||||
Research & Development | 491.5M | 460.1M | 446.6M | 385.8M | 398.8M |
Selling, General & Administrative | 1.1B | 1.0B | 954.7M | 815.6M | 789.3M |
Other Operating Expenses | -29.5M | -24.6M | -30.4M | -26.2M | -30.0M |
Total Operating Expenses | 1.6B | 1.5B | 1.4B | 1.2B | 1.2B |
Operating Income | 637.9M | 568.9M | 625.7M | 844.0M | 612.4M |
Operating Margin % | 16.0% | 15.5% | 17.4% | 25.0% | 19.6% |
Non-Operating Items | |||||
Interest Income | 500.0K | 1.1M | 1.2M | 1.7M | 1.5M |
Interest Expense | 16.0M | 15.8M | 4.1M | 9.1M | 24.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 579.3M | 437.5M | 580.5M | 774.5M | 524.4M |
Income Tax | 154.3M | 114.5M | 140.1M | 175.6M | 121.5M |
Effective Tax Rate % | 26.6% | 26.2% | 24.1% | 22.7% | 23.2% |
Net Income | 425.1M | 322.8M | 440.5M | 598.2M | 402.7M |
Net Margin % | 10.7% | 8.8% | 12.3% | 17.7% | 12.9% |
Key Metrics | |||||
EBITDA | 943.1M | 841.8M | 875.6M | 1.1B | 825.4M |
EPS (Basic) | €3.67 | €3.03 | €3.84 | €5.08 | €3.42 |
EPS (Diluted) | €3.64 | €3.01 | €3.82 | €5.06 | €3.41 |
Basic Shares Outstanding | 117765668 | 118154233 | 117946146 | 118265377 | 118146538 |
Diluted Shares Outstanding | 117765668 | 118154233 | 117946146 | 118265377 | 118146538 |
Income Statement Trend
bioMérieux S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 449.8M | 352.4M | 552.6M | 803.5M | 389.2M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 792.3M | 728.6M | 740.1M | 590.6M | 597.9M |
Inventory | 1.0B | 908.5M | 737.2M | 620.0M | 541.9M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 2.5B | 2.2B | 2.2B | 2.2B | 1.7B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.7B | 1.6B | 1.4B | 1.3B | 1.2B |
Goodwill | 2.0B | 1.9B | 2.2B | 1.8B | 1.7B |
Intangible Assets | 492.0M | 528.7M | 624.9M | 411.5M | 430.8M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 9.1M | 7.4M | 12.9M | 12.5M | 14.2M |
Total Non-Current Assets | 3.3B | 3.1B | 3.0B | 2.4B | 2.3B |
Total Assets | 5.8B | 5.3B | 5.2B | 4.6B | 3.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 272.4M | 265.1M | 269.4M | 239.5M | 207.1M |
Short-term Debt | 141.0M | 163.5M | 187.0M | 99.7M | 128.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 109.3M | 105.8M | 122.5M | 95.9M | 96.2M |
Total Current Liabilities | 1.1B | 1.1B | 1.1B | 955.9M | 924.0M |
Non-Current Liabilities | |||||
Long-term Debt | 349.2M | 355.4M | 318.4M | 362.8M | 352.4M |
Deferred Tax Liabilities | 25.7M | 11.1M | 53.0M | 60.3M | 105.8M |
Other Non-Current Liabilities | 500.0K | -400.0K | 100.0K | -100.0K | -100.0K |
Total Non-Current Liabilities | 424.6M | 419.4M | 412.6M | 485.5M | 522.5M |
Total Liabilities | 1.6B | 1.5B | 1.5B | 1.4B | 1.4B |
Equity | |||||
Common Stock | 12.0M | 12.0M | 12.0M | 12.0M | 12.0M |
Retained Earnings | 432.2M | 357.6M | 452.4M | 601.1M | 404.4M |
Treasury Stock | 42.9M | 19.1M | 36.0M | 10.3M | 23.1M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.2B | 3.8B | 3.6B | 3.2B | 2.5B |
Key Metrics | |||||
Total Debt | 490.2M | 518.9M | 505.4M | 462.5M | 481.3M |
Working Capital | 1.4B | 1.1B | 1.1B | 1.2B | 737.6M |
Balance Sheet Composition
bioMérieux S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 425.1M | 322.8M | 440.5M | 598.2M | 402.7M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 23.4M | 19.7M | 13.0M | 12.4M | 9.9M |
Working Capital Changes | -50.4M | -206.7M | -165.8M | -47.0M | -85.4M |
Operating Cash Flow | 419.4M | 149.0M | 276.6M | 573.7M | 369.5M |
Investing Activities | |||||
Capital Expenditures | -336.4M | -331.9M | -269.3M | -270.1M | -252.8M |
Acquisitions | -13.4M | -158.7M | -43.3M | -3.3M | -6.3M |
Investment Purchases | -1.2M | - | -10.5M | -400.0K | -2.3M |
Investment Sales | - | 1.8M | - | - | - |
Investing Cash Flow | -359.8M | -488.8M | -528.1M | -307.3M | -265.2M |
Financing Activities | |||||
Share Repurchases | - | - | -157.2M | -3.8M | -18.4M |
Dividends Paid | -100.2M | -100.2M | -101.2M | -73.1M | -22.5M |
Debt Issuance | 9.8M | 38.9M | 67.7M | 18.2M | 292.0M |
Debt Repayment | -84.6M | -73.7M | -53.4M | -68.3M | -426.5M |
Financing Cash Flow | -175.0M | -135.0M | -244.2M | -127.0M | -176.2M |
Free Cash Flow | 321.5M | 107.1M | 188.4M | 534.6M | 305.3M |
Net Change in Cash | -115.4M | -474.8M | -495.7M | 139.4M | -71.9M |
Cash Flow Trend
bioMérieux S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
35.00
Forward P/E
27.88
Price to Book
3.57
Price to Sales
3.78
Profitability Ratios
Profit Margin
10.86%
Operating Margin
16.82%
Return on Equity
10.68%
Return on Assets
7.23%
Financial Health
Current Ratio
2.20
Debt to Equity
11.65
Beta
0.45
Per Share Data
EPS (TTM)
€3.64
Book Value per Share
€35.66
Revenue per Share
€33.80
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bim | 15.0B | 35.00 | 3.57 | 10.68% | 10.86% | 11.65 |
Eurofins Scientific | 12.2B | 30.01 | 3.53 | 8.68% | 6.05% | 88.06 |
Lumibird S.A | 400.6M | 70.00 | 2.02 | 2.91% | 2.71% | 81.34 |
Eurofins Cerep SAS | 92.8M | 12.97 | - | 10.49% | 17.67% | 0.46 |
Klea Holding | 64.5M | 17.87 | 2.27 | 5.35% | 8.14% | 21.13 |
Predilife S.A | 12.3M | - | - | -4,653.75% | 97.76% | -1.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.